Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Anticancer Drug-Phospholipid Conjugate for Enhancement of Intracellular Drug Delivery.

Literature DB >> 20930942

Anticancer Drug-Phospholipid Conjugate for Enhancement of Intracellular Drug Delivery.

Taewon Hwang¹, Hee Dong Han, Chung Kil Song, Hasoo Seong, Jung Hyun Kim, Xiaoyuan Chen, Byung Cheol Shin.

Abstract

Tumor specific delivery of anti-cancer drugs is one of the major challenges faced by drug development processes. In this study, we prepared a doxorubicin (DOX)-conjugated liposome (DCL) by incorporating the newly synthesized DSPE-PEG2000-DOX (DPD) into liposomes as a lipid component and tested its anti-tumor activity in vivo. DPD was synthesized by coupling DOX to DSPE-PEG2000-COOH via amide linkage and the chemical structure of resulting DPD was confirmed by (1)H-NMR analysis. DCL having liposome size of 130 nm was prepared through thin film cast-hydration method. DCL was found to have significantly higher cellular uptake than conventional liposomes as confirmed by flow cytometry analysis. Anti-tumor activity of DCL against murine B16F10 melanoma tumor-bearing mice revealed that DCL inhibits tumor growth more efficiently than the conventional liposomes, presumably attributed to DOX mediated endocytosis process.

Entities: Chemical Disease Species

Year: 2007 PMID： 20930942 PMCID： PMC2949968 DOI： 10.1002/masy.200750318

Source DB: PubMed Journal: Macromol Symp ISSN： 1022-1360

9 in total

1. Drug transport mechanisms in HL60 cells isolated for resistance to adriamycin: evidence for nuclear drug accumulation and redistribution in resistant cells.

Authors: D Marquardt; M S Center
Journal: Cancer Res Date: 1992-06-01 Impact factor: 12.701

2. Transport studies of doxorubicin in model membranes indicate a difference in passive diffusion across and binding at the outer and inner leaflets of the plasma membrane.

Authors: G Speelmans; R W Staffhorst; B de Kruijff; F A de Wolf
Journal: Biochemistry Date: 1994-11-22 Impact factor: 3.162

3. Interaction specificity of the anthracyclines with deoxyribonucleic acid.

Authors: E J Gabbay; D Grier; R E Fingerle; R Reimer; R Levy; S W Pearce; W D Wilson
Journal: Biochemistry Date: 1976-05-18 Impact factor: 3.162

4. Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimetic.

Authors: Xiao-Bing Xiong; Yue Huang; Wan-Liang Lu; Xuan Zhang; Hua Zhang; Tsuneji Nagai; Qiang Zhang
Journal: J Control Release Date: 2005-10-03 Impact factor: 9.776

5. Folate receptor targeted biodegradable polymeric doxorubicin micelles.

Authors: Hyuk Sang Yoo; Tae Gwan Park
Journal: J Control Release Date: 2004-04-28 Impact factor: 9.776

6. In vivo distribution and antitumor activity of heparin-stabilized doxorubicin-loaded liposomes.

Authors: Hee Dong Han; Aeri Lee; Chung Kil Song; Taewon Hwang; Hasoo Seong; Chong Ock Lee; Byung Cheol Shin
Journal: Int J Pharm Date: 2006-02-23 Impact factor: 5.875

7. The P-glycoprotein-mediated relative decrease in cytosolic free drug concentration is similar for several anthracyclines with varying lipophilicity.

Authors: H S Mülder; H Dekker; H M Pinedo; J Lankelma
Journal: Biochem Pharmacol Date: 1995-09-28 Impact factor: 5.858

8. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases.

Authors: G Haran; R Cohen; L K Bar; Y Barenholz
Journal: Biochim Biophys Acta Date: 1993-09-19

9. Examination by laser scanning confocal fluorescence imaging microscopy of the subcellular localisation of anthracyclines in parent and multidrug resistant cell lines.

Authors: H M Coley; W B Amos; P R Twentyman; P Workman
Journal: Br J Cancer Date: 1993-06 Impact factor: 7.640

9 in total

6 in total

Anticancer Drug-Phospholipid Conjugate for Enhancement of Intracellular Drug Delivery.

1. Drug transport mechanisms in HL60 cells isolated for resistance to adriamycin: evidence for nuclear drug accumulation and redistribution in resistant cells.

2. Transport studies of doxorubicin in model membranes indicate a difference in passive diffusion across and binding at the outer and inner leaflets of the plasma membrane.

3. Interaction specificity of the anthracyclines with deoxyribonucleic acid.

4. Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimetic.

5. Folate receptor targeted biodegradable polymeric doxorubicin micelles.

6. In vivo distribution and antitumor activity of heparin-stabilized doxorubicin-loaded liposomes.

7. The P-glycoprotein-mediated relative decrease in cytosolic free drug concentration is similar for several anthracyclines with varying lipophilicity.

8. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases.

9. Examination by laser scanning confocal fluorescence imaging microscopy of the subcellular localisation of anthracyclines in parent and multidrug resistant cell lines.

1. Long-Circulating Amphiphilic Doxorubicin for Tumor Mitochondria-Specific Targeting.

2. Effects of doxorubicin-encapsulating AG73 peptide-modified liposomes on tumor selectivity and cytotoxicity.

3. Doxorubicin (DOX) Gadolinium-Gold-Complex: A New Way to Tune Hybrid Nanorods as Theranostic Agent.

4. Lactoferrin-modified PEGylated liposomes loaded with doxorubicin for targeting delivery to hepatocellular carcinoma.

5. Enhanced localization of anticancer drug in tumor tissue using polyethylenimine-conjugated cationic liposomes.

6. Gd(III)-DOTA-modified sonosensitive liposomes for ultrasound-triggered release and MR imaging.